Haleon plc (HLN)vsNeurocrine Biosciences Inc (NBIX)
HLN
Haleon plc
$9.12
+1.79%
HEALTHCARE · Cap: $40.34B
NBIX
Neurocrine Biosciences Inc
$163.88
-2.07%
HEALTHCARE · Cap: $16.06B
Smart Verdict
WallStSmart Research — data-driven comparison
Haleon plc generates 256% more annual revenue ($11.03B vs $3.10B). NBIX leads profitability with a 21.5% profit margin vs 15.1%. NBIX appears more attractively valued with a PEG of 0.45. NBIX earns a higher WallStSmart Score of 81/100 (A-).
HLN
Buy63
out of 100
Grade: C+
NBIX
Exceptional Buy81
out of 100
Grade: A-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 92.0% YoY
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Generating 1.3B in free cash flow
Growing faster than its price suggests
Revenue surging 42.2% year-over-year
Earnings expanding 2311.0% YoY
Safe zone — low bankruptcy risk
Keeps 22 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
0.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HLN
The strongest argument for HLN centers on EPS Growth, Price/Book, Operating Margin. Profitability is solid with margins at 15.1% and operating margin at 23.2%.
Bull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Revenue Growth, EPS Growth. Profitability is solid with margins at 21.5% and operating margin at 22.8%. Revenue growth of 42.2% demonstrates continued momentum.
Bear Case : HLN
The primary concerns for HLN are PEG Ratio, Revenue Growth.
Bear Case : NBIX
The primary concerns for NBIX are Piotroski F-Score.
Key Dynamics to Monitor
HLN profiles as a value stock while NBIX is a growth play — different risk/reward profiles.
NBIX carries more volatility with a beta of 0.40 — expect wider price swings.
NBIX is growing revenue faster at 42.2% — sustainability is the question.
HLN generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (81/100 vs 63/100), backed by strong 21.5% margins and 42.2% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haleon plc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Haleon plc (HLN) is a leading global consumer health company, formed as a spin-off from GlaxoSmithKline, that specializes in delivering innovative health solutions through its extensive portfolio of trusted brands, including Sensodyne, Panadol, and Voltaren. With a focus on key health segments such as oral care, pain relief, and dietary supplements, Haleon leverages strong brand recognition to meet the evolving needs of consumers. The company's commitment to sustainability and continuous innovation positions it strategically for long-term growth, aimed at enhancing health outcomes and delivering shareholder value through targeted investments and ongoing product development.
Visit Website →Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?